Advertisement
Home Tags Immunotherapy

Tag: Immunotherapy

Maintenance Peanut Oral Immunotherapy Effective for Preschoolers

0

Majority of children reach tolerance great enough to protect them from accidental exposure to peanuts

Lorlatinib Superior to Crizotinib for ALK-Positive NSCLC

Genetic Ancestry Tied to Lung Cancer Mutations in Latin Americans

0

Mutation frequencies of EGFR and KRAS were 30 and 10 percent, respectively, and 23 and 13 percent, respectively, for Mexican and Colombian patients

ASH: CAR T-Cell Therapy Promising for Relapsed/Refractory iNHL

0

Phase 2 study reveals high objective response rate for CAR T-cell therapy in patients with follicular lymphoma, marginal zone lymphoma

NHLBI Updates Guidance for Management of Asthma

0

Guidance focuses on tailored treatment interventions for specific age groups based on disease severity

Dexamethasone May Hinder Immunotherapy for Glioblastoma

0

Findings seen in preclinical studies of mice, survival data from patients receiving PD-(L)1 blockade for GBM

AI Model May Predict Immunotherapy Response in Melanoma

0

Histology slides, clinical data used to predict immune checkpoint inhibitor response in advanced melanoma

Nivolumab combined with cabozantinib is superior to sunitinib alone for the treatment of advanced clear cell renal cell carcinoma

Immunotherapy Combo Treats Advanced Kidney Cancer

0
First results show survival benefit with nivolumab plus cabozantinib versus sunitinib
For children and young adults receiving CD19 chimeric antigen receptor T-cell infusion

Infection Risk Up in Month After CAR T-Cell Immunotherapy

0
Infection rates increase in patients with ALL aged ≤26 years in first month, then decrease at days 29 to 90
Adding tucatinib to trastuzumab and capecitabine is associated with improved progression-free and overall survival among heavily pretreated patients with human epidermal growth factor receptor 2-positive metastatic breast cancer

SABCS: Addition of Tucatinib Ups Survival in HER2+ Metastatic Breast Cancer

0
In heavily pretreated patients, adding tucatinib versus placebo improves overall, progression-free survival
The June 2018 U.S. Food and Drug Administration label restriction on first-line immunotherapy for advanced bladder cancer was associated with a decrease in immunotherapy use and an increase in chemotherapy use

FDA Labeling Restriction Quickly Reflected in Oncology Practice

0
FDA label change linked to decrease in immunotherapy use, increases in chemotherapy use, PD-L1 testing